Menu
Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo's mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.4 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,5 improve CCHD screening in newborns,6 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.7-10 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,11 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.12 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient's physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo's family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™.
52 Discovery
Irvine, California 92618-3105
Phone: 19492977000
www.masimo.com
Activist investor Politan Capital Management on Tuesday said it owns a nearly 9% stake in Masimo Corp and plans to push the medical device maker to make changes, sending the company’s share price up 6%. Politan, founded by veteran investor Quentin Koffey, said in a regulatory filing it believes the company’s stock price is undervalued. […]
These are the stocks posting the largest moves before the bell.
Activist investor Politan Capital on Tuesday disclosed an 8.4% stake in medical device maker Masimo Corp, according to a U.S. Securities and Exchange Commission filing. (Reporting by Amruta Khandekar; Editing by Krishna Chandra Eluri)
Masimo Corp. (MASI) rose 3.9% in after hours trading after a report that an activist investor has taken a 9% stake.Politan Capital, founded by veteran activist Quentin Koffey, has a…
The medical-device company’s shares plummeted earlier this year when it entered into an ill-received acquisition deal.
The medical-device company’s shares plummeted earlier this year when it entered into an ill-received acquisition deal.
Masimo Corporation (NASDAQ: MASI ) delivered adjusted earnings per share (ETF:EPS) of $1.35 in the second quarter of 2022, up 43.6% year over year. The figure surpassed the Zacks Consensus Estimate by 13.5%. The adjustments include acquisition, integration and related costs, and acquired intangible asset amortization expenses, among others. GAAP EPS for the quarter was 33 cents, down by 62.5% from the year-earlier figure. Revenues in Detail Masimo registered revenues of $565.3 million in the second quarter, up 85.3% year over year on a reported basis. The figure also surpassed the Zacks Consensus Estimate by 4.3%. Per management, the year-over-year uptick in revenues was primarily driven by strength in its healthcare business. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, were 77,100 in the second quarter of 2022, up 6.3% from the prior-year period. Segmental Details Masimo derives its revenues from two business sources — healthcare and non-healthcare.
https://www.investing.com/news/pro/masimo-corp-pt-raised-to-179-at-needham--company-432SI-2869127
Masimo Corp''s (NASDAQ: MASI ) Q2 revenue increased 85.3% Y/Y to $565.3 million, beating the consensus of $540.56 million. Healthcare revenue was $357.0 million, +17% on reported basis and 19.0% on constant currency. Non-healthcare revenue was $208.3 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 77,100, +6.3%. Joe … Full story available on Benzinga.com
MASI earnings call for the period ending June 30, 2022.
Masimo Corporation (NASDAQ:NASDAQ:MASI) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Eli Kammerman - Vice President, Business Development and Investor…
The following slide deck was published by Masimo Corporation in conjunction with their 2022 Q2 earnings call.
Masimo (MASI) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close.The consensus EPS Estimate is $1.20 (+27.7% Y/Y) and the consensus Revenue Estimate…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release second quarter 2022 financial results for the period ended July 2, 2022, after the market closes on Tuesday, August 9, 2022. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use t
Masimo (NASDAQ: MASI) today announced the findings of a randomized, controlled trial published in the Journal of Clinical Anesthesia in which Dr. Melody H.Y. Long and colleagues from the KK Women’s and Children’s Hospital in Singapore evaluated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine brain function monitoring, to reduce the amount of the drug sevoflurane
The best high-growth stocks for young investors is our topic today. Many of the high-growth darlings of the pandemic have remained under steady pressure during the first half of 2022. Signs of an imminent recession and geopolitical turmoil continue to drag down broader indices and growth-focused exchange-traded funds (ETFs). For instance, the iShares Russell Top 200 Growth ETF (NYSEARCA: IWY ) and the Vanguard Growth Index Fund ETF (NYSEARCA: VUG ) have fallen 27% and 28% year-to-date (YTD), respectively. Meanwhile, the S&P 500 index has fallen 18% over the same period. Yet, investing regularly over many decades is known to be a great wealth creator for retail investors. Let’s assume that you are now 25, with $1,000 in savings and that you plan to retire at age 65. You decide to invest that $1,000 in a fund now and make an additional $3,000 of contributions annually at the start of each year. You have 40 years to invest. The annual return is 7%, compounded once a year. At the end of 40 years, the total amount saved becomes goes well over $650,000.
Masimo shocked investors by announcing that they would be buying Sound United. How will the acquisition impact MASI stock? Click here to find out.
The MASIMO CORPORATION POLITICAL ACTION COMMITTEE successfully filed their F3XA QUATERLY YEAR-END with the coverage period of 07/01/2021 to 12/31/2021 and a confirmation ID of FEC-1606817 *********CommitteeId: C00493940 | FilingId: 1606817 | FormType: F3XA | CoverageFrom: 07/01/2021 | CoverageThrough: 12/31/2021 | ReportType: QUATERLY YEAR-END*********